Abstract: The present disclosure relates to testing, analysis and treatment of an environment, wherein one or more baseline(s) is established for the environment. Systems and methods for detecting, treating, comparing and testing for mold, mold spores and mold fragments physically present or in the air of an environment are disclosed herein, as well as methods for remediating the effects of mold in the environment.
Abstract: The present disclosure relates to methods of collecting and testing bacteria containing samples from within the gastrointestinal (GI) tract of a subject. The methods may include disposing an ingestible device in the GI tract, collecting a bacteria-containing sample from the GI tract, selectively lysing eukaryotic cells in the sample by combining the sample with a dried reagent, exposing bacteria in the sample to resazurin in the ingestible device to produce resorufin, emitting light from the ingestible device, the emitted light being filtered through an optical filter to control for scatter so that the light interacts with the resorufin to produce fluorescence, and measuring a total fluorescence from the resorufin; or a rate of change of fluorescence from the resorufin as a function of time within the GI tract of the subject; and correlating the measured parameter to a number of viable bacterial cells in the sample.
Type:
Grant
Filed:
March 10, 2021
Date of Patent:
January 10, 2023
Assignee:
Biora Therapeutics, Inc.
Inventors:
Sharat Singh, Mitchell Lawrence Jones, Christopher Loren Wahl
Abstract: The present invention relates to a nanoperforator having a lipid-bilayer nanodisc and a membrane-structured protein surrounding the nanodisc and to a pharmaceutical composition having the nanoperforator as an active ingredient for preventing or treating viral infectious diseases. The use of the lipid-bilayer nanoperforator provided in the present invention can lead to the safe prevention or treatment of a disease caused by viral infection regardless of whether the virus is a variant or not, and thus the present invention can be widely used for the safe and effective treatment of viral infectious diseases.
Type:
Grant
Filed:
July 14, 2017
Date of Patent:
January 3, 2023
Assignee:
MVRIX CO., LTD.
Inventors:
Dae-Hyuk Kweon, Byoungjae Kong, Woo-Jae Chung, Baik Lin Seong, Sukchan Lee
Abstract: A method for modulating cellular activity in a subject, consisting essentially of the steps: (i) forming a liquid composition, (ii) subjecting the liquid composition to sequential harmonic oscillation to provide a liquid biochemical scaffold and, (iii) delivering a therapeutically effective amount of said liquid biochemical scaffold to said subject.
Abstract: The invention relates to methods for generating multipotent mammary stem cells from isolated and cultured human breast luminal cells. The method comprises the steps: 1. isolating and growing normal differentiated cells in vitro; 2. treating the differentiated cells with either a conditioned medium from active fibroblasts or cytokine. The invention also relates to multipotent mammary stem cells, cultures of the multipotent stem cells, differentiated cells, tissues, organs derived from the culture multipotent stem cells isolated by the methods disclosed and therapeutic and other uses for those cells thereof.
Type:
Grant
Filed:
July 9, 2018
Date of Patent:
November 29, 2022
Assignee:
KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE
Inventors:
Abdelilah Aboussekhra, Huda H. Al-Khalaf, Hazem Ghebeh
Abstract: The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of pl
Type:
Grant
Filed:
December 10, 2018
Date of Patent:
August 30, 2022
Assignee:
CSL BEHRING GmbH
Inventors:
Hung Pham, Jeffrey Michael Hey, Darren Nguy
Abstract: The present invention relates to a cell culture support comprising a substrate and a polymeric blend layer bound to the substrate. The polymeric blend layer comprises at least one thermoresponsive polymer and at least one coupling agent. The coupling agent is a non-protein coupling agent that has functional thiol, ester, epoxy, or aldehyde groups. The cell culture support further includes cells supported by the polymeric blend layer, wherein the thermoresponsive polymer provides for temperature induced detachment of the cells and/or cell sheets.
Abstract: The present invention is related to compositions comprising clarified limulus amebocyte lysate (LAL), wherein the LAL is substantially free of coagulogen and methods of making such compositions. The invention further relates to a method of detecting an endotoxin in a sample using a chromogenic assay, the method comprising: (a) contacting the sample with a reagent comprising clarified LAL and a chromogenic substrate; and (b) measuring a chromogenic effect resulting from a change in the chromogenic substrate in the presence of endotoxin in the sample, wherein the LAL is substantially free of coagulogen. The invention also relates to kits comprising clarified LAL substantially free of coagulogen, and methods of making such.
Type:
Grant
Filed:
January 11, 2018
Date of Patent:
June 7, 2022
Inventors:
Candice Stumbaugh, Leben Tadesse, Karen Lin
Abstract: Embodiments of the invention relate generally to protein extraction and, more generally, to bone protein extraction methods that do not require demineralization. In one embodiment, the invention provides a method comprising: mixing a bone sample and a quantity of an extraction buffer comprising: ammonium phosphate dibasic; or ammonium phosphate dibasic and ammonium bicarbonate; or ammonium phosphate dibasic, ammonium bicarbonate, and guanidine HCl; or sodium phosphate dibasic and sodium bicarbonate; or sodium phosphate dibasic, sodium bicarbonate, and guanidine HCl; or potassium phosphate dibasic and potassium bicarbonate; or potassium phosphate dibasic, potassium bicarbonate, and guanidine HCl; and incubating the bone sample/extraction buffer mixture.
Abstract: Thin parylene C membranes having smooth front sides and ultrathin regions (e.g., 0.01 ?m to 5 ?m thick) interspersed with thicker regions are disclosed. The back sides of the membranes can be rough compared with the smooth front sides. The membranes can be used in vitro to grow monolayers of cells in a laboratory or in vivo as surgically implantable growth layers, such as to replace the Bruch's membrane in the eye. The thin regions of parylene are semipermeable to allow for proteins in serum to pass through, and the thick regions give mechanical support for handling by a surgeon. The smooth front side allows for monolayer cell growth, and the rough back side helps prevents cells from attaching there.
Type:
Grant
Filed:
June 16, 2016
Date of Patent:
May 3, 2022
Assignees:
California Institute of Technology, University of Southern California
Abstract: The present disclosure provides methods for determining an etiology of upper and/or lower eyelid puffiness by examining a subject with squinted eyes; and determining if upper and/or lower eyelid puffiness does not improve, improves, partially improves, or worsens, wherein the etiology of the upper and/or lower eyelid puffiness is diagnosed to be anterior to the orbicularis oculi muscle if the puffiness does not improve, wherein the etiology of the upper and/or lower eyelid puffiness is determined to be posterior to the orbicularis oculi muscle if the puffiness improves, wherein the etiology of the upper and/or lower eyelid puffiness is determined to be anterior and posterior to the orbicularis oculi muscle if the puffiness partially improves, or wherein the puffiness is determined to be secondary to hypertrophy of the orbicularis muscle or if the puffiness worsens.
Abstract: The present application relates to a freeze-dried polymer composition containing chitosan and at least one lyoprotectant, a process for preparing a freeze-dried composition containing chitosan and at least one lyoprotectant and the use of a reconstituted freeze-dried chitosan composition to prepare implants for tissue repair.
Type:
Grant
Filed:
February 20, 2015
Date of Patent:
March 29, 2022
Assignee:
Ortho Regenerative Technologies Inc.
Inventors:
Anik Chevrier, Michael D. Buschmann, Daniel Veilleux, Caroline Hoemann, Marc Lavertu
Abstract: An enzymatic processing plant for continuous flow-based enzymatic processing of organic molecules. The enzymatic processing plant including an enzymatic processing area, wherein the enzymatic processing area includes a turbulence-generating pipe with a repeatedly changing centre-line and/or a repeatedly changing cross-section, for generating turbulence to mix a reaction mixture and prevent sedimentation of particles as the reaction mixture is flowing through the turbulence-generating pipe. The enzymatic processing plant and the enzymatic processing area are arranged such that the reaction mixture is subjected to turbulence within the enzymatic processing area for a reaction time of 15 minutes or more.
Abstract: The invention surprisingly found that Lactobacillus plantarum subsp. plantarum PS128 provides an advantageous effect in treatment or prevention of tic disorders and basal ganglia disorders. Accordingly, the invention provides a method of treating or preventing a movement disorder in a subject, comprising administering to a subject an effective amount of cells of a Lactobacillus plantarum subsp. plantarum PS128, which is deposited under DSMZ Accession No. DSM 28632.
Type:
Grant
Filed:
July 19, 2016
Date of Patent:
March 29, 2022
Assignees:
BENED BIOMEDICAL CO., LTD., ASIAN PROBIOTICS AND PREBIOTICS CORPORATION
Abstract: The present invention relates to a method and system for aseptic material transfer from a storage container to a bioreactor. More precisely the invention relates to a method and system for aseptically transferring dry material, such as microcarriers for cell cultivation, to a bioreactor, comprising transferring microcarriers from a first container housing said microcarriers to a bioreactor for cell cultivation via r transfer tubing connecting the first container to the bioreactor, wherein the transfer is accomplished with pressurized air or gas supplied to the container.
Type:
Grant
Filed:
May 16, 2016
Date of Patent:
January 18, 2022
Assignee:
Cytiva Sweden AB
Inventors:
Bjorn Johan Lundgren, Emmanuel Macedo, Ann-Christin Magnusson, Lena Maria Sandberg
Abstract: The present invention provides solid formulations of hyaluronic acid (HA) that are resistant to degradation into low molecular weight species of HA and yet can be readily dissolved in water. The compositions comprise sodium hyaluronate, cyclo-dextrin, sodium benzoate, and potassium sorbate, wherein said composition is in powder form.
Abstract: A closed-loop insulin delivery system is described. More particularly, the presently disclosed insulin delivery system can comprise glucose-responsive vesicles that release insulin in response to hypoxia triggered by enzymatic reduction of glucose. In addition or as an alternative to insulin, the delivery system can release other diabetes treatment agents, such as non-insulin-based diabetes treatment agents. The vesicles can be prepared from a hypoxia sensitive polymer, such as a hypoxia-sensitive hyaluronic acid (HS-HA). The HS-HA can comprise hydrophobic groups that can be reduced in hypoxic environments to form hydrophilic groups. The vesicles can be loaded into microneedles and microneedle array patches for use in the treatment of diabetes or to otherwise regulate blood glucose levels in subjects in need of such treatment.
Abstract: Novel methods and apparatus are disclosed for cell culture and cell recovery. The methods and apparatus simplify the process of cell separation from media, minimize potential damage to gas permeable devices during fluid handling, and allow closed system automated cell culture and cell recovery from gas permeable devices.
Abstract: Orally administered physiologically acceptable anti-biofilm compositions comprising enzymes and if desired additional components such as antimicrobials, antibiotics, antifungals, herbals, chelating agents, lactoferrin and related compounds, minerals, surfactants, binders, and fillers useful for the inhibition and treatment of gastrointestinal biofilms in humans. Physiologically acceptable anti-biofilm compositions containing these enzymes are useful in the inhibition, reduction and/or treatment of gastrointestinal biofilm infections, and associated systemic symptoms caused by biofilms associated microorganisms within the gastrointestinal tract. Methods of identification, preparation and use of such physiologically acceptable anti-biofilm compositions are also provided.
Abstract: The invention discloses a method for measurement of peptidic degradation products of a proteolytic cascade in biological samples, especially blood samples, wherein the sample is incubated until a steady state equilibrium is reached for at least one peptidic degradation product involved in said proteolytic cascade and wherein said at least one peptidic degradation product in steady state equilibrium of the proteolytic cascade is quantified in the sample.
Type:
Grant
Filed:
May 5, 2017
Date of Patent:
August 3, 2021
Assignee:
ATTOQUANT DIAGNOSTICS GMBH
Inventors:
Marko Poglitsch, Cornelia Schwager, Hans Loibner, Manfred Schuster